References
  • Data on file. Janssen Therapeutics, Division of Janssen Products, LP
  • Mills AM, Nelson M, Jayaweera D, et al. Once-daily darunavir/ritonavir vs lopinavir/ritonavir in treatment-naïve, HIV-1-infected patients: 96-week analysis. AIDS. 2009;23:1679-1688.
  • National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the NCEP Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3_rpt.htm. Accessed January 24, 2011.
  • PREZISTA® [package insert]. Raritan, NJ: Janssen Therapeutics, Division of Janssen Products, LP November 2011.
  • Madruga JV, Berger D, McMurchie M, et al. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomized controlled phase III trial. Lancet. 2007;370:49-58.
  • Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 10, 2011; 1-161.
    http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed January 19, 2011.
  • De La Rosa G, Pattery T, Picchio G, et al. Changing prevalence of darunavir resistance-associated mutations in clinical samples received for routine resistance testing: 2003‐2009. Poster presented at: 10th International Congress on Drug Therapy in HIV Infection; November 7‐11, 2010; Glasgow, UK.
The PREZISTA ZONELatest DHHS Guidelines Patient ResourcesSite Satisfaction Survey

>